Cathepsin S plays an important role in the pathogenesis of several cardiovascular diseases; however, the relationship between serum cathepsin S and cerebral infarction (CI) is still unknown. This study aimed to investigate the relationship between acute phase serum cathepsin S level and cerebral infarction. A total of 202 stroke patients were enrolled into this study, and were divided into cerebral infarction (n = 140) group and non-cerebral infarction group (non-CI, n = 62). Fifty healthy individuals were recruited as the control group. Serum levels of cathepsin S and cystatin C were measured at days 1, 7, and 14 posthospitalization. Compared to the non-CI group, the CI group had significantly higher rates of hypertension, dyslipidemia, and smoking (all P < 0.05). The CI group had significantly higher cathepsin S levels and cathepsin S to cystatin C ratio (CatS/CysC) at both days 1 and 7 posthospitalization (both P < 0.05).
| INTRODUCTION
Cerebral infarction (CI) refers to an area of focal necrotic brain tissue due to prolonged or complete ischemia in the local blood flow, usually causing cognitive impairment, disability, or death. 1 CI is the most common type of stroke, accounting for approximately 80% of all stroke cases. 2 It is reported that the annual stroke mortality rate is 157 per 100 000 in China, which has become the first leading cause of adult death. 3 Identifying novel biomarkers of CI may be helpful for the development of innovative strategies to prevent or treat this disease.
Dynamic remodeling of extracellular matrix (ECM) is implicated in many physiological processes, such as branching morphogenesis, angiogenesis, wound healing, and normal organ homeostasis. 4 Cathepsin S is a member of lysosomal cysteine proteinase family and plays an important role in the ECM remodeling. 5 On the other hand, cystatin C is a powerful inhibitor of cathepsin L and S. 6 Therefore, regulating the balance between cathepsin S and cystatin C is crucial for the physiological/pathological functions of cysteine proteinase. 7 Given the crucial role of ECM remodeling in physiological processes, dysregulation of cathepsin S has been shown to be associated with several pathological conditions, such as cardiovascular disease 8 and cancers. 9 Accumulating evidence has suggested that cathepsin S plays an important role in a range of cardiovascular diseases, such as atherosclerosis, 7,10-13 abdominal aortic aneurysm 14 neointima formation, [15] [16] [17] in-stent restenosis, 17 and cardiac repair after myocardial infarction. 18 During the pathological process of atherosclerosis, cathepsin S plays a key role in ECM remodeling. 12, [19] [20] [21] For instance, Sukhova et al. have reported that cathepsin S is upregulated in atherosclerotic sites, 22 and may be involved in the destabilization and rupture of atherosclerotic plaques. 19, 20 By contrast, cystatin C is decreased in atherosclerosis site. higher cathepsin S serum levels, and combined serum Cat S and hs-CRP levels may provide a sensitive predictive marker of abdominal aortic aneurysm. 24 All these studies indicated that serum cathepsin S level has the diagnostic value for cardiovascular diseases.
Even though the association between serum cathepsin S level and cardiovascular disease has been revealed in several studies, the relationship between serum cathepsin S and CI remains to be investigated. As atherosclerosis-induced artery stenosis in the neck or head is a common cause of CI, we hypothesized that cathepsin S may be involved in the pathological process of CI. Therefore, the purpose of this study was to elucidate the relationship between serum cathepsin S level at acute phase and CI as well as the diagnostic value of cathepsin S for CI. The effects of the serum cathepsin S to cystatin C ratio (CatS/CysC) on these issues were also evaluated. 
| PATIENTS AND METHODS

| Patients
| Data collection
The demographic and clinical characteristics were recorded. Lifestyle including smoking and drinking as well as medical history including hypertension, hyperlipidemia, diabetes, coronary heart disease, rheumatic heart disease, atrial fibrillation, blood disease, and other vascular diseases were also recorded.
For all stroke patients, serum cathepsin S and cystatin C levels were determined at days 1, 7, and 14 posthospitalization. The cathepsin S and cystatin C levels in the healthy control group were determined within 3 days after enrollment. Serum cathepsin S and cystatin C levels were measured using a Human Cathepsin S ELISA Kit (Shanghai Qisheng Biological Preparation Co., Ltd., China) and a Cystatin C Assay Kit (immunoturbidimetry method, Beijing Leadman, China), respectively, with an automatic analyzer (Roche, Germany) according to the manufacturer's protocols.
Plaque properties and stenosis degree were measured using a two-dimensional color ultrasound (LOGIQ VID7, GE Healthcare, USA) with a 10 MHz probe.
The degree of stenosis was assessed using the NASCET (North American Symptomatic Carotid Endarterectomy Trial) stenosis grading criteria: measurement of cerebral blood vessels using the NASCET stenosis grading method. Briefly, stenosis rate was calculated by the follow- Plaque properties were defined according to the location, shape, and echo intensity of the plaque in the ultrasound examination as follows: homogeneous hypoechoic lipid plaques were defined as soft plaques; plaques with strong echoes and sound shadows were defined as calcified plaques; ulcerative plaques with uneven echo intensity were defined as mixed plaques. The calcified plaques were defined as stable plaque, whereas the soft plaque and mixed plaque were defined as unstable plaque.
| Statistical analysis
Continuous data including age, levels of cathepsin S and cystatin C, CatS/CysC were indicated with the mean ± SD. Means were compared by Student independent t test or one-way ANOVA and Fisher's LSD test as posthoc. Univariate and multivariate logistic regression models were used to investigate the association between independent variables and CI (with or without). Receiver operating characteristic (ROC) curve analysis was further utilized to check the diagnostic effectiveness of significant variables. The statistical significance level for all the tests was set at a P-value <0.05. All analyses were performed using IBM SPSS Version 20 (SPSS Statistics V20, IBM Corporation, Somers, New York).
3 | RESULTS
| Patient's characteristics
A total of 202 stroke patients were enrolled into this study, and were divided into CI (n = 140) group and non-cerebral infarction group (non-CI, n = 62) based on their diagnosis of CI. Meanwhile, 50 healthy individuals were recruited as the control group. 
T A B L E 2 Measurement of cathepsin S (CatS) and cystatin C (CysC)
Parameters Healthy control (n = 50) Non-CI (n = 62) CI (n = 140) The cathepsin S and cystatin C levels in the healthy control group were determined within 3 days after enrollment.
As shown in Table 1 , there were significant differences in the gender and age among the three groups (both P < 0.01). In addition, the CI group had significantly higher rates of hypertension, dyslipidemia, smoking as compared with the non-CI group (all P < 0.05).
In the CI group, there were 62.96% unilateral stenoses and 
| Measurements of serum levels of cathepsin S and cystatin C
The serum levels of cathepsin S and cystatin C were measured at days 1, 7, and 14 after the onset of stroke for all stroke patients. For the healthy control group, cathepsin S and cystatin C levels were measured and recorded as the day 1 data. As shown in Table 2 , there were significance in cathepsin S level and cathepsin S to cystatin C ratio (CatS/CysC) among groups. The CI group had significantly higher cathepsin S levels and CatS/CysC at both days 1 and 7 posthospitalization as compared with the non-CI group and control group (both P < 0.05).
The serum levels of cathepsin S and cystatin C were compared between patients with lacunar infarcts (n = 24) and nonlacunar infarcts (n = 116). As shown in Table 3 , patients with lacunar infarcts had significantly lower CatS level and CatS/CysC ratio than those with the rest of CIs at day 7 posthospitalization.
The serum levels of cathepsin S and cystatin C were compared between patients with stable plague (n = 77) and unstable plague (n = 125). As shown in Table 4 , patients with stable plague had significantly higher CatS/CysC ratio than those with unstable plague at day 7 posthospitalization (P < 0.05). The difference in CatS level between stable plague and unstable plague group reached marginal significance (P = 0.055).
| Associated factors for CI
To identify the associated factors with CI, univariate and multivariate logistic regressions were used to fit the models between CI and other independent variables. The results showed that the cathepsin S level at day 7 posthospitalization and age were the significantly associated variables in both univariate and multivariate analyses after adjusting for patient's gender, history of diseases, and smoking and clinical conditions (all P < 0.05, Table 5 ). The CatS/CysC at days 1 and 7 posthospitalization were also significantly associated with CI (both P < 0.05, Tables 6 and 7 ). In the model with CatS/CysC at day 1, age, hypertension, and dyslipidemia were also associated with CI (all P < 0.05, Table 6 ). Abbreviations: CI, confidence interval; OR, odds ratio. Univariate and multivariate logistic regression models were used to analyze the association between independent variables and patient with cerebral infarction.
T A B L E 3 Comparison of the serum levels of cathepsin S and cystatin C between patients with lacunar infarcts and nonlacunar infarcts
| The diagnostic performance of CatS and CatS/CysC for CI
To evaluate if the identified associated factors could be a diagnostic indicator for CI, ROC analysis was used to fit the relation. As shown in Figure 1A , cathepsin S at day 7 posthospitalization (CatS-day7) had an Area Under Curve (AUC) value of 0.726 (95% CI: 0.652-0.800, 
| DISCUSSION
In this study, we investigated the relationship between acute phase serum cathepsin S level and CI. The results showed that the CI group had significantly higher rates of hypertension, dyslipidemia, smoking than the non-CI group (all P < 0.05). The CI group had significantly higher cathepsin S levels and cathepsin S to cystatin C ratio (CatS/CysC) at both days 1 and 7 posthospitalization than the non-CI group and control group (both P < 0.05). In addition, multivariate logistic regression analysis demonstrated that cathepsin S level (at day 7 posthospitalization, CatSday7) and CatS/CysC (at days 1 and 7 posthospitalization) were the asso- Our results showed that the CI group had significantly higher rates of hypertension, dyslipidemia, smoking as compared with the non-CI group, which is consistent with the fact that hypertension, dyslipidemia, and smoking are all well-documented risk factors for CI. [25] [26] [27] It has been shown that cathepsin S plays an important role in the pathogenesis of atherosclerosis, and intracranial arterial stenosis caused by atherosclerosis is a common cause of CI. These observations suggest a possible role for cathepsin S in CI. Hence, we attempted to elucidate the association between serum cathepsin S and CI in the current study. Given the crucial role of cathepsin S in ECM remodeling, the elevated serum level of cathepsin S has been reported in several cardiovascular diseases, such as atherosclerosis, 14 atherosclerotic stenosis, 11 myocardial infarction, 18 and abdominal aortic aneurysm. 24 In agreement with these reports, our study showed that serum cathepsin S level was upregulated in patients with CI at acute phase. In addition, patients with CI had a higher CatS/CysC at the acute phase of CI. showed that patients with lacunar infarcts had significantly lower CatS level and CatS/CysC ratio than those with the rest of CIs at day 7 posthospitalization, indicating a milder disease condition.
On the other hand, our multivariate logistic regression analysis further showed that serum cathepsin S level and CatS/CysC at acute phase were the associated factors with CI. ROC analysis further demonstrated that serum cathepsin S level and CatS/CysC at acute phase were the potential diagnostic biomarkers for CI. To our best knowledge, this is the first study revealing the association between serum cathepsin S level and CI. It is worthy of further investigation to explore if atherosclerosis is involved in the underlying mechanism of the association between serum cathepsin S and CI.
There are still some limitations in this study. First, the non-CI group consisted of a variety of non-CI stroke patients, and the heterogeneity of clinical background in the non-CI group may interfere with the analysis outcome. In addition, patients within 3 days of symptom onset were included in this study, and the serum sample was collected at days 1, 7, and 14 posthospitalization. Therefore, the time of serum collection was not precisely at days 1, 7, and 14 poststroke for some patients, which would affect the analysis. The sample size of this study was relatively small. Furthermore, our multivariate logistic regression analysis demonstrated that cathepsin S levels were associated with CI at day 7 posthospitalization but not at days 1 and 14 posthospitalization. The discrepancy may be attributed to the time of serum collection and was not unified at days 1, 7, and 14 poststroke for all patients and the small sample size of this study. In the future, a well-designed prospective study with a large F I G U R E 1 A, ROC function of cathepsin S at day 7 posthospitalization (CatS-day7) to with or without cerebral infarction. B, ROC function of cathepsin S to cystatin C ratio (CatS/CysC) at day 1 posthospitalization to with or without cerebral infarction. C, ROC function of cathepsin S to cystatin C ratio (CatS/CysC) at day 7 to with or without cerebral infarction sample size should be conducted to validate the findings of the current study. All these limitations should be addressed in the following study.
In summary, our study demonstrated that cathepsin S and CatS/ CysC at acute phase were associated with CI, and may have the potential to be the diagnostic biomarkers for CI. Our preliminary findings are helpful for better understanding the relationship between serum cathepsin S level and CI. Further investigation is needed to validate these findings.
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